Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of Metap (type Ii)

dc.contributor.author Yılmaz, Özgür
dc.contributor.author Bayer, Burak
dc.contributor.author Bekçi, Hatice
dc.contributor.author Uba, Abdullahi, I
dc.contributor.author Cumaoğlu, Ahmet
dc.contributor.author Yelekçi, Kemal
dc.contributor.author Küçükgüzel, S. Guniz
dc.date.accessioned 2020-09-25T09:17:58Z
dc.date.available 2020-09-25T09:17:58Z
dc.date.issued 2020
dc.description.abstract Background: Prostate cancer is still one of the serious causes of mortality and morbidity in men. Despite recent advances in anticancer therapy, there is a still need of novel agents with more efficacy and specificity in the treatment of prostate cancer. Because of its function on angiogenesis and overexpression in the prostate cancer, methionine aminopeptidase-2 (MetAP-2) has been a potential target for novel drug design recently. Objective: A novel series of Flurbiprofen derivatives N-(substituted)-2-(2-(2-fluoro-[1,1'-biphenyl]-4-il)propanoyl)hydrazinocarbothioamide (3a-c), 4-substituted-3 -(1 -(2-fluoro-[1,1'-biphenyl]-4-yl)ethyl)-1H-1,2,4-triazole-5(4H)-thione (4a-d), 3-(substitutedthio)-4-(substituted-pheny1)5-(1-(2-fluoro-[1,1'-biphenyt]-4-yl)ethyl)-411-1,2,4-triazole (5a-y) were synthesized. The purpose of the research was to evaluate these derivatives against MetAP-2 in vitro and in silico to obtain novel specific and effective anticancer agents against prostate cancer. Methods: The chemical structures and purities of the compounds were defined by spectral methods (H-1-NMR, C-13-NMR, HR-MS and FT-IR) and elemental analysis. Anticancer activities of the compounds were evaluated in vitro by using MTS method against PC-3 and DU-143 (androgenindependent human prostate cancer cell lines) and LNCaP (androgen-sensitive human prostate adenocarcinoma) prostate cancer cell lines. Cisplatin was used as a positive sensitivity reference standard. Results: Compounds 5b and 5u; 3c, 5b and 5y; 4d and 5o showed the most potent biological activity against PC3 cancer cell line (IC50 = 27.1 mu M, and 5.12 mu M, respectively), DU-145 cancer cell line (IC50 - 11.55 mu M, 6.9 mu M and 9.54 mu M, respectively) and LNCaP cancer cell line (IC50 - 11.45 mu M and 26.91 mu M, respectively). Some compounds were evaluated for their apoptotic caspases protein expression (EGFR/PI31C/AKT pathway) by Western blot analysis in androgen independent-PC3 cells. BAX, caspase 9, caspsase 3 and anti-apoptotic BcL-2 mRNA levels of some compounds were also investigated. In addition, molecular modeling studies of the compounds on MetAP-2 enzyme active site were evaluated in order to get insight into binding mode and energy. Conclusion: A series of Flurbiprofen-thioether derivatives were synthesized. This study presented that some of the synthesized compounds have remarkable anticancer and apoptotic activities against prostate cancer cells. Also, molecular modeling studies exhibited that there is a correlation between molecular modeling and anticancer activity results. en_US
dc.description.sponsorship Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) en_US
dc.identifier.doi 10.2174/1573406415666190613162322 en_US
dc.identifier.issn 1573-4064
dc.identifier.issn 1875-6638
dc.identifier.scopus 2-s2.0-85090373391 en_US
dc.identifier.uri https://hdl.handle.net/20.500.12469/3445
dc.identifier.uri https://doi.org/10.2174/1573406415666190613162322
dc.language.iso en en_US
dc.publisher Bentham Science PUBL LTD en_US
dc.relation.ispartof Medicinal Chemistry
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject EGFR/PI3K/AKT pathway en_US
dc.subject LNCaP en_US
dc.subject Flurbiprofen en_US
dc.subject Thioether en_US
dc.subject Methionine aminopeptidase en_US
dc.subject Prostate cancer en_US
dc.title Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of Metap (type Ii) en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.institutional Yelekçi, Kemal en_US
gdc.bip.impulseclass C4
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department Fakülteler, Mühendislik ve Doğa Bilimleri Fakültesi, Biyoinformatik ve Genetik Bölümü en_US
gdc.description.endpage 749 en_US
gdc.description.issue 6 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 735 en_US
gdc.description.volume 16 en_US
gdc.description.wosquality Q3
gdc.identifier.openalex W2995166239
gdc.identifier.pmid 31203805 en_US
gdc.identifier.wos WOS:000566839700003 en_US
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.diamondjournal false
gdc.oaire.impulse 8.0
gdc.oaire.influence 2.77166E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Male
gdc.oaire.keywords Methionine aminopeptidase
gdc.oaire.keywords Prostate cancer
gdc.oaire.keywords Molecular Structure
gdc.oaire.keywords LNCaP
gdc.oaire.keywords Metalloendopeptidases
gdc.oaire.keywords Prostatic Neoplasms
gdc.oaire.keywords Antineoplastic Agents
gdc.oaire.keywords Sulfides
gdc.oaire.keywords Aminopeptidases
gdc.oaire.keywords Structure-Activity Relationship
gdc.oaire.keywords EGFR/PI3K/AKT pathway
gdc.oaire.keywords Drug Delivery Systems
gdc.oaire.keywords Flurbiprofen
gdc.oaire.keywords Cell Line, Tumor
gdc.oaire.keywords Humans
gdc.oaire.keywords Thioether
gdc.oaire.popularity 8.311714E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 0301 basic medicine
gdc.oaire.sciencefields 0303 health sciences
gdc.oaire.sciencefields 03 medical and health sciences
gdc.openalex.collaboration National
gdc.openalex.fwci 1.10646564
gdc.openalex.normalizedpercentile 0.76
gdc.openalex.toppercent TOP 1%
gdc.opencitations.count 10
gdc.plumx.crossrefcites 1
gdc.plumx.facebookshareslikecount 240
gdc.plumx.mendeley 16
gdc.plumx.pubmedcites 2
gdc.plumx.scopuscites 11
gdc.relation.journal Medicinal Chemistry
gdc.scopus.citedcount 11
gdc.virtual.author Yelekçi, Kemal
gdc.wos.citedcount 10
relation.isAuthorOfPublication 9407938e-3d31-453b-9199-aaa8280a66c5
relation.isAuthorOfPublication.latestForDiscovery 9407938e-3d31-453b-9199-aaa8280a66c5
relation.isOrgUnitOfPublication 71ce8622-7449-4a6a-8fad-44d881416546
relation.isOrgUnitOfPublication 2457b9b3-3a3f-4c17-8674-7f874f030d96
relation.isOrgUnitOfPublication b20623fc-1264-4244-9847-a4729ca7508c
relation.isOrgUnitOfPublication.latestForDiscovery 71ce8622-7449-4a6a-8fad-44d881416546

Files